NasdaqCM - Nasdaq Real Time Price • USD
Fennec Pharmaceuticals Inc. (FENC)
As of 11:30 AM EDT. Market Open.
Earnings Estimate
CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
---|---|---|---|---|
No. of Analysts | 5 | 5 | 5 | 4 |
Avg. Estimate | 0.26 | 0.01 | 0.23 | 1.04 |
Low Estimate | -0.08 | -0.05 | -0.05 | 0.61 |
High Estimate | 1.54 | 0.04 | 0.52 | 1.4 |
Year Ago EPS | -0.23 | -0.21 | -0.6 | 0.23 |
Revenue Estimate
CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
---|---|---|---|---|
No. of Analysts | 5 | 5 | 4 | 5 |
Avg. Estimate | 18.88M | 11.49M | 50.2M | 71.44M |
Low Estimate | 9.54M | 10.6M | 43.93M | 53.5M |
High Estimate | 53.55M | 12.46M | 54.36M | 85.2M |
Year Ago Sales | 1.68M | 3.33M | 21.25M | 50.2M |
Sales Growth (year/est) | 1,025.80% | 245.60% | 136.20% | 42.30% |
Earnings History
CURRENCY IN USD | 3/31/2023 | 6/30/2023 | 9/30/2023 | 12/31/2023 |
---|---|---|---|---|
EPS Est. | -0.21 | -0.16 | -0.12 | -0.02 |
EPS Actual | -0.23 | -0.21 | -0.07 | -0.1 |
Difference | -0.02 | -0.05 | 0.05 | -0.08 |
Surprise % | -9.50% | -31.20% | 41.70% | -400.00% |
EPS Trend
CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
---|---|---|---|---|
Current Estimate | 0.26 | 0.01 | 0.23 | 1.04 |
7 Days Ago | 0.26 | 0.01 | 0.23 | 1.04 |
30 Days Ago | 0.28 | 0.01 | 0.16 | 0.9 |
60 Days Ago | -0.01 | 0.03 | 0.2 | 0.69 |
90 Days Ago | -0.02 | 0.02 | 0.2 | 0.69 |
EPS Revisions
CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
---|---|---|---|---|
Up Last 7 Days | -- | -- | -- | -- |
Up Last 30 Days | -- | -- | -- | -- |
Down Last 7 Days | -- | -- | -- | -- |
Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
CURRENCY IN USD | FENC | Industry | Sector | S&P 500 |
---|---|---|---|---|
Current Qtr. | 213.00% | -- | -- | 1.50% |
Next Qtr. | 104.80% | -- | -- | 12.10% |
Current Year | 138.30% | -- | -- | 4.40% |
Next Year | 352.20% | -- | -- | 13.20% |
Next 5 Years (per annum) | -- | -- | -- | 10.97% |
Past 5 Years (per annum) | -- | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
Maintains | HC Wainwright & Co.: Buy to Buy | 4/4/2024 |
Maintains | Craig-Hallum: Buy to Buy | 3/18/2024 |
Maintains | HC Wainwright & Co.: Buy to Buy | 8/4/2023 |
Reiterates | HC Wainwright & Co.: Buy to Buy | 6/21/2023 |
Maintains | Cantor Fitzgerald: Overweight | 4/6/2023 |
Reiterates | HC Wainwright & Co.: Buy | 4/4/2023 |
Related Tickers
NGEN.V NervGen Pharma Corp.
2.0800
+2.97%
NGENF NervGen Pharma Corp.
1.5300
+2.00%
TARA Protara Therapeutics, Inc.
2.9101
-4.59%
EPRX.TO Eupraxia Pharmaceuticals Inc.
3.7900
-2.82%
VSC.F 4SC AG
8.86
-0.23%
DSGN Design Therapeutics, Inc.
3.7450
-0.40%
IMMU.ST Mendus AB (publ)
0.4745
+0.96%
ANEB Anebulo Pharmaceuticals, Inc.
2.7036
+1.26%
SLNCF Silence Therapeutics plc
8.00
0.00%
CSBR Champions Oncology, Inc.
5.06
0.00%